In The News

Reformulary Group Inc. and Mednow Inc. partner to advance the mission of making medications more transparent, more accessible, and more affordable for all Canadians

By blending technological innovations, this groundbreaking partnership offers mutual patients more choice, better value, and easy access to expert advice related to drugs that provide the best healthcare value in a digital age. It also intends to extend affordable access to prescription drugs to groups such as gig workers- traditionally left out of most healthcare plans.

TORONTO–(BUSINESS WIRE)– Mednow Inc (TSXV: MNOW) (OTCQX:MDNWF) is proud to announce today that Reformulary Group Inc. has chosen Mednow as a preferred digital pharmacy, helping optimize the member experience of close to 300,000 and growing, subscribed members. Reformulary Group built and manages The Reformulary®, its proprietary drug list (formulary) becoming the most recognized independent formulary in Canada, along with the award-winning Drugfinder® search tool. Partnering with the Reformulary team, like-minded healthcare professionals, Mednow will offer managed formularies powered by Reformulary® to its ever-growing network of clients. The Reformulary-Mednow partnership leverages Reformulary’s built-in expert advice to help Canadians find the drug that provides the best healthcare (works better; costs less), together with a smart pharmacy that’s committed to providing lower prices for plan members. Reformulary plan members will also benefit from concierge support from Mednow pharmacists.

The partnership also includes the development of a combined offering to bring an exciting, affordable, and transparent drug solution to all Canadians. This includes people without or with little drug coverage, such as gig workers and others without drug plans. Founded on shared values, the two companies will work together toward the mutual goal of making drugs more affordable for more Canadians.

The Reformulary and its Drugfinder® search tool offer built-in expertise about which drugs provide the best value (clinical & cost), empowering people to proactively manage their health. The company also has a substantial prescription drug data asset used to mine and better understand the use of prescription drugs. With its focus on empowering people, Reformulary is launching a set of online tools, called meTrics™, for all Canadians to track their health and quality of life – since, You know you best™.

Mednow is a national virtual pharmacy in your pocket offering a personal, private and always-on digital pharmacy experience for all Canadians. Reformulary clients (and indeed all Canadians) enjoy fast, free prescription delivery as part of Mednow’s low dispensing fee as well as low drug cost and instant access to pharmacists for advice on the phone or in the Mednow app for iPhone/iPad, Android devices and on the web.

Components of the partnership include technological integrations making digital tools more accessible for mutual patients, virtual pharmacy services provided to Reformulary clients, the Reformulary will be offered to Mednow clients, an exciting solution for uninsured and underinsured Canadians.

About Mednow

Mednow (TSXV: MNOW) (OTCQX:MDNWF) is a healthcare technology company offering virtual access with a high-standard of care. Designed with accessibility and quality of care in mind, Mednow provides virtual pharmacy and telemedicine services as well as doctor home visits through an interdisciplinary approach to healthcare that is focused on the patient experience. Mednow’s services include free at-home delivery of medications, doctor consultations, a user-friendly interface for easy upload, transfer, and refill of prescriptions, access to healthcare professionals through an intuitive chat experience and the specialized PillSmart™ system that packages prescriptions in easy-to-use daily dose packs, each labelled with the date and time of the next dose.

About Reformulary

Reformulary Group is a leading healthcare company in Canada, enabled by technology. The most notable innovation is its proprietary list of prescription drugs (formulary) – The Reformulary. Championing better drugs plans for Canadian companies and Canadians. Reformulary Group is passionate about its work, as it knows how important it is for Canadians to have access to effective drugs at affordable prices.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements:

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information, including statements relating to: Mednow’s plan to expand its operations and open fulfillment centres in certain locations in 2022, Mednow’s goal of integrating the technology of its strategic business acquisitions with its core fulfillment pharmacies, the optimization of Mednow’s PillSmart TM and nutraceutical offerings, Mednow’s ability to connect with employers, specialty doctors and large pharmacies, and Mednow’s ability to acquire customers and lower costs.

Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Risk factors are set out in the Company’s final long form prospectus dated February 26, 2021 available for review on the Company’s profile at . Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

This news release also contains future-oriented financial information and financial outlook information (collectively, “FOFI”) as defined under Canadian securities laws, prepared by Mednow’s management about Mednow’s reasonably estimated prospective results of operations, revenue, sales, and components thereof, all of which are subject to the same assumptions, risks factors, limitations and qualifications set forth in the above paragraphs. Readers are cautioned that FOFI are not guarantees of future performance, and should not be considered as such, since actual results may differ materially from those expressed in FOFI. Mednow and its management believe that FOFI has been prepared on a reasonable basis, reflecting management’s best estimates and judgements. FOFI contained in this news release were made as of the date of this news release and is provided for the purpose of describing the belief of Mednow’s management of the anticipated effects of the financing on Mednow’s business operations.

As a result, there can be no assurance that forward-looking information or FOFI will prove to be accurate, as actual results and future events could differ materially from those anticipated in this news release. Accordingly, readers should not place undue reliance on the forward-looking information or FOFI contained in this news release. Mednow does not undertake any obligation to publicly update or revise any forward-looking information or FOFI other than as required under applicable securities laws.

Investor contact:
Lorraine Cardenas

Reformulary Media Contact:
Lyn Whitham

T: 647-527-3579

Source: Mednow Inc.